Medicament and therapeutical method for treating idiopathic asthenozoospermia

Abstract

A therapeutical method is disclosed for treating idiopathic asthenozoospermia which comprises orally or parenterally administering to a patient in need thereof a combination preparation comprising in admixture L-carnitine and acetyl L-carnitine or the pharmacologically acceptable salts thereof, in substantially equimolar amouts.

What is claimed is:  
     
         1 . An orally or parenterally administrable combination preparation comprising in admixture L-carnitine and acetyl L-carnitine or the pharmacologically acceptable salts thereof, in a molar ratio ranging from 1.5:1 to 1:1.5.  
     
     
         2 . The preparation of  claim 1 , wherein said molar ratio is 1:1.  
     
     
         3 . The preparation of  claim 1  in unit dosage form comprising from 0.33 g to 0.22 g of L-carnitine inner salt and from 0.28 g to 0.42 g of acetyl L-carnitine or equimolar amounts of the pharmacologically acceptable salts thereof.  
     
     
         4 . The preparation of  claim 2  in unit dosage form comprising 0.22 g of L-carnitine inner salt and 0.28 g of acetyl L-carnitine inner salt or equimolar amounts of the pharmacologically acceptable salts thereof.  
     
     
         5 . The preparation of  claim 1  wherein the pharmacologically acceptable salt of L-carnitine and acetyl L-carnitine is selected form the group comprising: chloride; bromide; iodide; aspartate, particularly acid aspartate; citrate, particularly acid citrate; tartrate; phosphate, particularly acid phosphate; fumarate, particularly acid fumarate; 
 glycerophosphate; glucose phosphate; lactate; maleate, particularly acid maleate; orotate; oxalate, particularly acid oxalate; sulphate, particularly acid sulphate; trichloroacetate; trifluoro acetate and methanesulphonate.  
 
     
     
         6 . A therapeutical method for treating idiopathic asthenozoospermia which comprises orally or parenterally administering to a patient in need thereof a combination preparation comprising in admixture L-carnitine and acetyl L-carnitine or the pharmacologically acceptable salts thereof, in a molar ratio ranging from 1.5:1 to 1:1.5.  
     
     
         7 . The method of  claim 6 , wherein said molar ratio is 1:1.  
     
     
         8 . The method of  claim 6  which comprises orally or parenterally administering to said patients in a single or multiple dose administration regimen a total amount of 0.60-1.0 g/day of L-carnitine inner salt and 0.80-1.3 g/day of acetyl L-carnitine inner salt or equimolar amounts of the pharmacologically acceptable salts thereof.